In the Boardroom
Refine Search
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
The France-based biotechnology company Novasep has announced Nadege Laborde as the new president of its industrial biotech business unit. 6 December 2013
Pharmaceutical
The UK’s ‘Golden Triangle’ of biotech innovation can compete on the world stage, AstraZeneca (LSE: AZN) chief executive Pascal Soriot told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
Pharmaceutical
Japan’s largest drugmaker, Takeda Pharmaceutical, says that Christophe Weber has been approved at the company's board of directors meeting to become chief operating officer and candidate as the next chief executive of the company. 29 November 2013
Pharmaceutical
US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has named Yong-Jun Liu as the company’s new head of research. 20 November 2013
Pharmaceutical
UK-based biotech company Immunocore has appointed Jonathan Knowles as the new executive chairman of the board of directors with immediate effect. 20 November 2013
article
UK-based developer of inhaled therapies Vectura Group (LSE: VEC) has announced the appointment of Bruno Angelici to the board as an independent non-executive director and non-executive chairman designate. 20 November 2013
article
US-headquartered biotech company AmpliPhi BioSciences (OTCBB: APHB) has appointed Baxter Phillips III to the newly created position of vice president, corporate strategy and business development. 20 November 2013
article
German privately-owned biopharmaceutical company Affimed Therapeutics has appointed Jens-Peter Marschner as chief medical officer. 20 November 2013
Pharmaceutical
If there is one pharma company bucking the trend of shaky financial results it is the Clinigen Group. 15 November 2013
Pharmaceutical
To support its ongoing success as a BioPharma leader, US drug major Bristol-Myers Squibb says it is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization, and has announced a series of related changes within its senior management team. 14 November 2013
Pharmaceutical
US biopharma company Endocyte (Nasdaq: ECYT) has announced that Colin Goddard has joined its board of directors. 13 November 2013
Pharmaceutical
AstraZeneca today announced that Marc Dunoyer has been appointed chief financial officer and will join the company board as an executive director, effective tomorrow. 31 October 2013
Generics
Israel-based Teva Pharmaceutical Industries, say that, despite its recent denials of a rift with its chief executive, its board of directors has agreed with Jeremy Levin that he will step down as president and CEO, just 18 months after assuming the positions at Teva, the world’s largest generics firm. 30 October 2013
Pharmaceutical
Merck KGaA announced today that Gerhard Schmitz will join the pharmaceutical, chemical and life science company as the new Head of Global Accounting from November 1. 30 October 2013
Pharmaceutical
Mergers and acquisitions are common – 111 M&As took place in the UK in the second quarter of 2013 alone – yet there is no ‘one-size fits all’ formula to ensure smooth transitions, writes Chris Molloy, chief executive at RSA, executive search and interim management experts to the life sciences industry. 22 October 2013
Biotechnology
Acorda Therapeutics has announced that Michael Rogers has joined the company as chief financial officer. 9 October 2013
article
Ablynx has announced that Peter Fellner, Bo Jesper Hansen and William Jenkins will be proposed for nomination as Independent Non-Executive Directors at the company's forthcoming extraordinary meeting of its shareholders to be held on November 7. 8 October 2013
Pharmaceutical
US drugmaker Forest Laboratories (NYSE: FRX) saw its shares rise 2.5% to $44.50 yesterday (September 10), after it announced the appointment of Brenton Saunders as its chief executive officer and president, effective from October 1. 11 September 2013
Biotechnology
With a clear passion for helping patients and a self-confessed need to know everything that is happening "on the shopfloor," Jan-Anders Karlsson is arguably a pharma chief executive like no other, writes TPL's Sophie Flowers after an interview with the man himself. 22 July 2013
Biotechnology
US clinical-stage biotech Nura Bio today closed announced a more than $140 million in Series A financing.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze